Who
Krish S. Krishnan
President and CEO
Company insider
Files Form 4 as: President and CEO, Krystal Biotech; Chief Operating Officer, Precigen; COO, CFO and Secretary, New River Pharmaceuticals.
In numbers
- Trades disclosed
- 375
- Buys
- 4
- Sells
- 43
- Bought
- $2.3M
- Sold
- $168.9M
- Companies
- 3
- Companies where not an officer
- 0
- First trade
- 29 Mar 2005
- Last trade
- 4 Sep 2026
- Last filed
- 4 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 4 Sep 2026filed 4 Sep 2026 | KRYS Krystal BiotechBiotechnology | SEC FORM 4 Sold | $184K520 at $354.54 | filing |
| 4 Sep 2026filed 4 Sep 2026 | KRYS Krystal BiotechBiotechnology | SEC FORM 4 Sold | $208K573 at $363.34 | filing |
| 4 Sep 2026filed 4 Sep 2026 | KRYS Krystal BiotechBiotechnology | SEC FORM 4 Sold | $495K1,358 at $364.48 | filing |
| 4 Sep 2026filed 4 Sep 2026 | KRYS Krystal BiotechBiotechnology | SEC FORM 4 Sold | $310K847 at $365.42 | filing |
| 4 Sep 2026filed 4 Sep 2026 | KRYS Krystal BiotechBiotechnology | SEC FORM 4 Sold | $148K405 at $366.56 | filing |
| 4 Sep 2026filed 4 Sep 2026 | KRYS Krystal BiotechBiotechnology | SEC FORM 4 Sold | $721K2,029 at $355.57 | filing |
| 4 Sep 2026filed 4 Sep 2026 | KRYS Krystal BiotechBiotechnology | SEC FORM 4 Sold | $1.2M3,297 at $356.37 | filing |
| 4 Sep 2026filed 4 Sep 2026 | KRYS Krystal BiotechBiotechnology | SEC FORM 4 Sold | $1.4M3,981 at $357.57 | filing |
| 4 Sep 2026filed 4 Sep 2026 | KRYS Krystal BiotechBiotechnology | SEC FORM 4 Sold | $1.1M3,143 at $358.42 | filing |
| 4 Sep 2026filed 4 Sep 2026 | KRYS Krystal BiotechBiotechnology | SEC FORM 4 Sold | $1.2M3,357 at $359.39 | filing |
| 4 Sep 2026filed 4 Sep 2026 | KRYS Krystal BiotechBiotechnology | SEC FORM 4 Sold | $817K2,266 at $360.46 | filing |
| 4 Sep 2026filed 4 Sep 2026 | KRYS Krystal BiotechBiotechnology | SEC FORM 4 Sold | $439K1,214 at $361.61 | filing |
| 4 Sep 2026filed 4 Sep 2026 | KRYS Krystal BiotechBiotechnology | SEC FORM 4 Sold | $729K2,010 at $362.65 | filing |
| 4 Sep 2026filed 4 Sep 2026 | KRYS Krystal BiotechBiotechnology | SEC FORM 4 Sold | $184K520 at $354.54 | filing |
| 4 Sep 2026filed 4 Sep 2026 | KRYS Krystal BiotechBiotechnology | SEC FORM 4 Sold | $721K2,029 at $355.57 | filing |
| 4 Sep 2026filed 4 Sep 2026 | KRYS Krystal BiotechBiotechnology | SEC FORM 4 Sold | $1.2M3,297 at $356.37 | filing |
| 4 Sep 2026filed 4 Sep 2026 | KRYS Krystal BiotechBiotechnology | SEC FORM 4 Sold | $1.4M3,981 at $357.57 | filing |
| 4 Sep 2026filed 4 Sep 2026 | KRYS Krystal BiotechBiotechnology | SEC FORM 4 Sold | $1.1M3,143 at $358.42 | filing |
| 4 Sep 2026filed 4 Sep 2026 | KRYS Krystal BiotechBiotechnology | SEC FORM 4 Sold | $1.2M3,357 at $359.39 | filing |
| 4 Sep 2026filed 4 Sep 2026 | KRYS Krystal BiotechBiotechnology | SEC FORM 4 Sold | $817K2,266 at $360.46 | filing |
News
Monte Rosa Therapeutics (NASDAQ:GLUE) versus Krystal Biotech (NASDAQ:KRYS) Head to Head SurveyKRYS · tickerreport.com · 21 Oct 2026Krystal Biotech Sees Broad Antitumor Activity With KB113 In Gorlin Syndrome; Stock UpKRYS · rttnews.com · 15 Oct 2026Krystal Biotech Reports Over 80% Lesion Regression With KB113 In Gorlin SyndromeKRYS · rttnews.com · 15 Oct 2026
0 headlines in the last 90 days name Krish S. Krishnan; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.